talquetamab will increase the stage or influence of ergotamine by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Check. Talquetamab will cause cytokine launch syndrome (CRS) that may suppress action of CYP enzymes, resulting in amplified exposure of CYP substrates.It can be crucial to notice that Bizarro K2 is illegitimate in